Eli Lilly & Co. (NYSE:LLY) had its price target increased by JPMorgan Chase & Co. from $59.00 to $61.00 in a research report sent to investors on Tuesday morning, American Banking and Market News reports. The firm currently has a neutral rating on the stock.
A number of other firms have also recently commented on LLY. Analysts at Zacks reiterated a neutral rating on shares of Eli Lilly & Co. (NYSE:LLY) in a research note to investors on Tuesday, September 3rd. They now have a $54.00 price target on the stock. Separately, analysts at Sanford C. Bernstein raised their price target on shares of Eli Lilly & Co. (NYSE:LLY) from $59.00 to $61.00 in a research note to investors on Thursday, August 15th. They now have an outperform rating on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Eli Lilly & Co. (NYSE:LLY) from $60.00 to $62.00 in a research note to investors on Wednesday, August 14th. They now have an outperform rating on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. Eli Lilly & Co. has a consensus rating of Hold and a consensus price target of $57.47.
Shares of Eli Lilly & Co. (NYSE:LLY) opened at 52.61 on Tuesday. Eli Lilly & Co. has a 1-year low of $44.88 and a 1-year high of $58.40. The stock’s 50-day moving average is $52.91 and its 200-day moving average is $53.64. The company has a market cap of $56.829 billion and a P/E ratio of 11.82.
Eli Lilly & Co. (NYSE:LLY) last posted its quarterly earnings results on Wednesday, July 24th. The company reported $1.16 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.01 by $0.15. The company had revenue of $5.93 billion for the quarter, compared to the consensus estimate of $5.82 billion. During the same quarter last year, the company posted $0.83 earnings per share. Eli Lilly & Co.’s revenue was up 5.9% compared to the same quarter last year. Analysts expect that Eli Lilly & Co. will post $4.14 EPS for the current fiscal year.
Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.